Among 36 analysts covering Wells Fargo & Company (NYSE:WFC), 17 have Buy rating, 5 Sell and 14 Hold. Therefore 47% are positive. Wells Fargo & Company has $75.0 highest and $44 lowest target. $58.25’s average target is -6.87% below currents $62.55 stock price. Wells Fargo & Company had 115 analyst reports since July 29, 2015 according to SRatingsIntel. The rating was maintained by Compass Point on Tuesday, January 19 with “Neutral”. As per Wednesday, April 12, the company rating was downgraded by Rafferty. Raymond James downgraded the shares of WFC in report on Tuesday, October 4 to “Underperform” rating. The stock of Wells Fargo & Company (NYSE:WFC) has “Sell” rating given on Tuesday, August 8 by Raymond James. Sandler O’Neill upgraded the stock to “Buy” rating in Tuesday, January 9 report. The firm has “Hold” rating given on Monday, November 28 by Jefferies. Jefferies maintained it with “Hold” rating and $6200 target in Friday, August 11 report. The company was upgraded on Tuesday, September 8 by Evercore. The stock of Wells Fargo & Company (NYSE:WFC) has “Hold” rating given on Wednesday, April 12 by Sandler O’Neill. Guggenheim upgraded the stock to “Neutral” rating in Wednesday, April 26 report.
Perrigo Company plc, together with its subsidiaries, develops, makes, markets, and distributes over-the-counter consumer goods and pharmaceutical products worldwide. The company has market cap of $12.93 billion. It offers OTC products in various categories, including cough, cold, allergy and sinus, analgesic, gastrointestinal, smoking cessation, infant formula and food, animal health, diagnostic products, natural health and vitamins, personal care and derma-therapeutics, lifestyle, and anti-parasite; consumer healthcare products; and vitamins, minerals, and supplements. It currently has negative earnings. The firm also provides generic and specialty pharmaceutical prescription drugs, such as creams, ointments, lotions, gels, shampoos, foams, suppositories, sprays, liquids, suspensions, solutions, powders, controlled substances, injectables, hormones, oral solid dosage forms, and oral liquid formulations.
Analysts await Perrigo Company plc (NYSE:PRGO) to report earnings on May, 28. They expect $1.23 EPS, down 0.81% or $0.01 from last year’s $1.24 per share. PRGO’s profit will be $173.23M for 18.66 P/E if the $1.23 EPS becomes a reality. After $1.39 actual EPS reported by Perrigo Company plc for the previous quarter, Wall Street now forecasts -11.51% negative EPS growth.
The stock decreased 0.21% or $0.19 during the last trading session, reaching $91.8. About 559,679 shares traded. Perrigo Company plc (PRGO) has declined 23.00% since January 13, 2017 and is downtrending. It has underperformed by 39.70% the S&P500.
Starboard Value Lp holds 22.03% of its portfolio in Perrigo Company plc for 9.64 million shares. North Tide Capital Llc owns 300,000 shares or 5.42% of their US portfolio. Moreover, Camber Capital Management Llc has 5.23% invested in the company for 975,000 shares. The Tennessee-based Moon Capital Management Llc has invested 4.29% in the stock. Greenlight Capital Inc, a New York-based fund reported 2.90 million shares.
Wells Fargo & Company, a diversified financial services company, provides retail, commercial, and corporate banking services to individuals, businesses, and institutions. The company has market cap of $308.01 billion. The Company’s Community Banking segment offers checking, savings, market rate, and individual retirement accounts, as well as time deposits and remittances; and lines of credit, automobile floor plan lines, equity lines and loans, equipment and transportation loans, education and residential mortgage loans, and debit and credit cards. It has a 16.16 P/E ratio. This segment also provides equipment leases, real estate and other commercial financing, small business administration financing, venture capital financing, cash management, payroll services, retirement plans, merchant payment processing, and private label financing solutions, as well as purchases retail installment contracts.